Drugs / Vitex agnus-castus BNO 1095
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06211049 | Dec 2023 → Jul 2025 | primary dysmenorrhea | Bionorica SE | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vitex agnus-castus BNO 1095 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06211049 ↗ |
| Route | Oral | “Vitex agnus-castus BNO 1095 20 mg or placebo tablets are taken orally (means by mouth) once a day during the treatment phase.” NCT06211049 ↗ |